Effects of operating parameters on the efficiency of liposomal encapsulation of enzymes

Hwang, Sang Youn; Kim, Hak Kyung; Choo, Jaebum; Seong, Gi Hun; Hien, Thai Bao Dieu; Lee, E.K.

doi:10.1016/j.colsurfb.2012.02.008

Cited by 51 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concentration of drug affects the %EE to a great extent (Hwang et al, 2012). As the concentration of drug increased, the %EE increased up to certain extent, after which no significant increase in %EE was observed (Figure 8).…”

Section: Effect Of Drug Concentrationmentioning

confidence: 85%

Applying quality by design (QbD) concept for fabrication of chitosan coated nanoliposomes

Pandey

Karande

Sonawane

et al. 2013

Journal of Liposome Research

View full text Add to dashboard Cite

In the present investigation, a quality by design (QbD) strategy was successfully applied to the fabrication of chitosan-coated nanoliposomes (CH-NLPs) encapsulating a hydrophilic drug. The effects of the processing variables on the particle size, encapsulation efficiency (%EE) and coating efficiency (%CE) of CH-NLPs (prepared using a modified ethanol injection method) were investigated. The concentrations of lipid, cholesterol, drug and chitosan; stirring speed, sonication time; organic:aqueous phase ratio; and temperature were identified as the key factors after risk analysis for conducting a screening design study. A separate study was designed to investigate the robustness of the predicted design space. The particle size, %EE and %CE of the optimized CH-NLPs were 111.3 nm, 33.4% and 35.2%, respectively. The observed responses were in accordance with the predicted response, which confirms the suitability and robustness of the design space for CH-NLP formulation. In conclusion, optimization of the selected key variables will help minimize the problems related to size, %EE and %CE that are generally encountered when scaling up processes for NLP formulations. The robustness of the design space will help minimize both intra-batch and inter-batch variations, which are quite common in the pharmaceutical industry.

show abstract

Section: Effect Of Drug Concentrationmentioning

confidence: 85%

Applying quality by design (QbD) concept for fabrication of chitosan coated nanoliposomes

Pandey

Karande

Sonawane

et al. 2013

Journal of Liposome Research

View full text Add to dashboard Cite

show abstract

“…Te m o z o l o m i d e -l i p o s o m e w a s p r e p a r e d b y a proliposomes method (14,15). Briefly, temozolomide (20 mg), soybean phospholipid (240 mg), and cholesterol (30 mg) were dissolved in methanol.…”

Section: Formulation Of Temozolomide-liposomesmentioning

confidence: 99%

Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation

Gao

Wang

Liu

et al. 2015

DD&T

View full text Add to dashboard Cite

Temozolomide plays a critical role in curing glioma at present. The purpose of this work was to develop a suitable drug delivery system which could prolong the half-life, improve the brain targeting, and reduce the systemic effect of the drug. Temozolomide-liposomes were formulated by the method of proliposomes. They were found to be relatively uniform in size of 156.70 ± 11.40 nm with a narrow polydispersity index (PI) of 0.29 ± 0.04. The average drug entrapment efficiency and loading capacity were 35.45 ± 1.48% and 2.81 ± 0.20%, respectively. The pH of temozolomide-liposomes was 6.46. In vitro release studies were conducted by a dynamic dialysis. The results showed that temozolomide released slowly from liposomes compared with the solution group. The release behavior of temozolomide-liposomes was in line with First-order kinetics and Weibull equation. The pharmacokinetics study was evaluated by pharmacokinetics parameters. The t(1/2β) and MRT of temozolomide-liposomes were 3.57 times and 1.27 times greater than that of temozolomide solution. The Cmax and AUC values of temozolomide-liposomes were 1.10 times and 1.55 times greater than that of temozolomide solution. The results of pharmacokinetics study showed temozolomide-liposomes prolonged the in vivo circulation time and increased AUC. Furthermore, the biodistribution in mice showed that temozolomide-liposomes preferentially decreased the accumulation of temozolomide in heart and lung and increased the drug concentration in brain after i.v. injection, which implied that temozolomide-liposomes improved the therapeutic effect in the brain and reduced the toxicity in lung and heart.

show abstract

“…Liposome surfaces can be easily functionalised with an appropriate ligand for targeted delivery and also decorated with protein-repellent polymers, such as PEG, to inhibit opsonization and clearance by the mononuclear phagocytic system (Immordino et al, 2006;Hwang et al, 2012;Pattni et al, 2015). Due to the fast development of nanomedicine, several protein delivery formulations based on liposomes have been developed for therapeutic use.…”

Section: Liposomesmentioning

confidence: 99%

Nanosized Delivery Systems for Therapeutic Proteins: Clinically Validated Technologies and Advanced Development Strategies

Moncalvo

Espinoza

Cellesi

2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The impact of protein therapeutics in healthcare is steadily increasing, due to advancements in the field of biotechnology and a deeper understanding of several pathologies. However, their safety and efficacy are often limited by instability, short half-life and immunogenicity. Nanodelivery systems are currently being investigated for overcoming these limitations and include covalent attachment of biocompatible polymers (PEG and other synthetic or naturally derived macromolecules) as well as protein nanoencapsulation in colloidal systems (liposomes and other lipid or polymeric nanocarriers). Such strategies have the potential to develop next-generation protein therapeutics. Herein, we review recent research progresses on these nanodelivery approaches, as well as future directions and challenges.

show abstract

Effects of operating parameters on the efficiency of liposomal encapsulation of enzymes

Cited by 51 publications

References 29 publications

Applying quality by design (QbD) concept for fabrication of chitosan coated nanoliposomes

Applying quality by design (QbD) concept for fabrication of chitosan coated nanoliposomes

Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation

Nanosized Delivery Systems for Therapeutic Proteins: Clinically Validated Technologies and Advanced Development Strategies

Contact Info

Product

Resources

About